Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
| Status: | Completed |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 3/29/2017 |
| Start Date: | May 2014 |
| End Date: | February 2016 |
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
The purpose of this study is to determine the safety, tolerability, and activity of extended
treatment with NGM282 in patients with Primary Biliary Cirrhosis.
treatment with NGM282 in patients with Primary Biliary Cirrhosis.
Inclusion Criteria:
- Completion of NGM 13-0103
- Males or females, between 18 and 75 years of age, inclusive
- PBC Diagnosis consistent with AASLD and EASL guidelines
- Stable dose of UDCA
Exclusion Criteria:
- Chronic liver disease of a non-PBC etiology
- Evidence of clinically significant hepatic decompensation
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials